Hospital
Swedish Health Services
Swedish Health Services was paid $13.34M by Medicaid between Jan 2018 and Dec 2024, across 213 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 15% of everything it billed.
33Billing provider infoSWEDISH HEALTH SERVICES
ISSAQUAH, WA 98029
ISSAQUAH, WA 98029
33aNPI1851686059assigned 06/15/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.34M
24GClaims395,184
24DCodes billed213
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#32 of 49
Median peer was paid$20.06M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,919 | $1.90M | |
| 2019 | 54,160 | $1.88M | |
| 2020 | 49,142 | $1.57M | |
| 2021 | 68,871 | $2.13M | |
| 2022 | 65,080 | $2.12M | |
| 2023 | 60,055 | $1.98M | |
| 2024incomplete | 49,957 | $1.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 6,761 | 5,695 | $2.04M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 13,099 | 12,417 | $1.51M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 7.6% | 2,803 | 2,754 | $1.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.4% | 12,179 | 11,233 | $983K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 6.1% | 1,627 | 1,599 | $817K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 9,883 | 9,129 | $739K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 5.4% | 2,407 | 2,370 | $724K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 3,588 | 3,439 | $606K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 1,490 | 1,457 | $274K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 2,320 | 2,187 | $271K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 2.0% | 626 | 615 | $266K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 2,997 | 2,862 | $260K |
201 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.9% | 2,149 | $258K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 2,758 | $231K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 2,524 | $229K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.7% | 3,291 | $227K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.6% | 1,022 | $216K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 8,315 | $210K |
| 76830 | Ultrasound, transvaginal | 1.4% | 2,273 | $189K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.3% | 2,037 | $171K |
| 76642 | 1.0% | 1,613 | $139K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 783 | $130K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 994 | $123K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,510 | $120K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,576 | $103K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,093 | $95K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 554 | $90K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,301 | $80K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,384 | $76K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 432 | $73K |
| 59025 | Fetal non-stress test | <1% | 493 | $71K |
| 76770 | <1% | 529 | $61K | |
| 93017 | <1% | 773 | $57K | |
| 80047 | <1% | 16,303 | $55K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 261 | $53K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,196 | $52K |
| 87631 | <1% | 756 | $49K | |
| 76536 | <1% | 573 | $44K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,817 | $44K |
| 80076 | <1% | 11,914 | $43K | |
| 97162 | <1% | 1,012 | $38K | |
| 70498 | <1% | 332 | $34K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,207 | $33K |
| 84484 | <1% | 8,061 | $31K | |
| G0378 | Hospital observation service, per hour | <1% | 4,216 | $24K |
| 77066 | Tomosynthesis, mammo | <1% | 760 | $22K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 215 | $21K |
| 70496 | <1% | 338 | $18K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,101 | $14K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,071 | $14K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 91 | $13K |
| 77065 | Tomosynthesis, mammo | <1% | 448 | $13K |
| 83605 | <1% | 2,500 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 718 | $12K |
| 93970 | <1% | 130 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,304 | $11K |
| 80053 | Comprehensive metabolic panel | <1% | 2,901 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,913 | $10K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 28 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,299 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,932 | $9K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,667 | $9K |
| 73610 | <1% | 570 | $9K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 14 | $9K |
| 73110 | <1% | 348 | $9K | |
| 73630 | <1% | 527 | $9K | |
| 76801 | <1% | 181 | $8K | |
| 93971 | <1% | 97 | $8K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 338 | $6K |
| 97161 | <1% | 125 | $6K | |
| 83880 | <1% | 1,540 | $6K | |
| 72100 | <1% | 349 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,265 | $6K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 97 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,080 | $5K |
| 85379 | <1% | 1,104 | $5K | |
| 74018 | <1% | 245 | $5K | |
| 73030 | <1% | 297 | $4K | |
| 84145 | <1% | 409 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,264 | $3K |
| 87040 | <1% | 577 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,587 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,552 | $3K |
| 73562 | <1% | 118 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,226 | $3K |
| 96376 | <1% | 3,123 | $2K | |
| 36000 | <1% | 158 | $2K | |
| 94729 | <1% | 78 | $2K | |
| 94726 | <1% | 52 | $2K | |
| 85027 | <1% | 1,665 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 195 | $1K |
| 82962 | <1% | 5,649 | $1K | |
| 93978 | <1% | 42 | $1K | |
| 71250 | <1% | 33 | $1K | |
| 84703 | <1% | 5,227 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,856 | $1K |
| 83735 | <1% | 1,392 | $968.58 | |
| 73564 | <1% | 96 | $907.91 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,322 | $773.19 |
| 94060 | <1% | 14 | $730.17 | |
| 86140 | <1% | 1,103 | $700.03 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,461 | $656.85 |
| 83690 | <1% | 6,848 | $656.49 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,539 | $648.87 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 39 | $620.97 |
| 73130 | <1% | 44 | $618.91 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,332 | $601.91 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 41 | $527.59 |
| 97163 | <1% | 14 | $513.25 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,816 | $477.52 |
| 82565 | <1% | 1,042 | $465.66 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,511 | $407.31 |
| 82553 | <1% | 67 | $392.14 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 74 | $390.74 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 47 | $378.51 |
| 72040 | <1% | 25 | $377.96 | |
| 87486 | <1% | 41 | $320.09 | |
| 87581 | <1% | 41 | $320.09 | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,272 | $311.58 |
| 85014 | <1% | 529 | $306.57 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,665 | $306.36 |
| 81003 | <1% | 6,096 | $305.86 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,850 | $293.08 |
| 97166 | <1% | 14 | $292.95 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,676 | $285.26 |
| 81001 | <1% | 3,390 | $272.84 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 514 | $264.19 |
| 85610 | <1% | 3,460 | $262.37 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,640 | $252.13 |
| 90715 | <1% | 15 | $246.17 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 570 | $210.10 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,305 | $199.51 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,481 | $191.35 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,569 | $179.02 |
| 76377 | <1% | 108 | $156.83 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,040 | $144.93 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 18 | $143.55 |
| 73140 | <1% | 26 | $137.96 | |
| 80305 | <1% | 500 | $136.16 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,682 | $129.33 |
| 88342 | <1% | 623 | $115.12 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,477 | $106.11 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 580 | $88.81 |
| J3490 | Unclassified drugs | <1% | 328 | $88.73 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,509 | $58.81 |
| 73502 | <1% | 13 | $49.18 | |
| 87210 | <1% | 171 | $42.14 | |
| 82803 | <1% | 350 | $40.15 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 213 | $30.90 |
| 84702 | <1% | 538 | $29.78 | |
| 85730 | <1% | 288 | $24.59 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,690 | $24.57 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 292 | $22.19 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,232 | $22.13 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,032 | $19.98 |
| 87186 | <1% | 231 | $17.35 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 194 | $14.02 |
| 87807 | <1% | 13 | $13.54 | |
| 81025 | <1% | 334 | $12.68 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 153 | $12.53 |
| 86901 | <1% | 212 | $12.03 | |
| 87070 | <1% | 45 | $9.88 | |
| 99152 | <1% | 58 | $8.77 | |
| 85651 | <1% | 27 | $8.67 | |
| 80179 | <1% | 370 | $7.62 | |
| 86850 | <1% | 13 | $6.89 | |
| 87205 | <1% | 60 | $6.32 | |
| 85652 | <1% | 28 | $6.27 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,105 | $6.23 |
| 86900 | <1% | 33 | $4.96 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,118 | $4.18 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 271 | $3.99 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,269 | $3.13 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $2.63 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 177 | $2.12 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 120 | $1.41 |
| 82550 | <1% | 104 | $1.33 | |
| A9270 | Non-covered item or service | 0% | 2,749 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 71 | $0.00 |
| 94761 | 0% | 284 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 43 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 394 | $0.00 |
| 88304 | 0% | 68 | $0.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 97 | $0.00 |
| C1769 | Guide wire | 0% | 112 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 38 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 84 | $0.00 |
| 87430 | 0% | 24 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 13 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 33 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 54 | $0.00 |
| 88341 | 0% | 13 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 88 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 19 | $0.00 |
| 87081 | 0% | 37 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 12 | $0.00 |
| 88307 | 0% | 13 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 52 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 284 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 97 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 99 | $0.00 |
| 82248 | 0% | 30 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 60 | $0.00 |
| 82947 | 0% | 25 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 85 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 132 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 28 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 94 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 63 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 37 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 15 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 8,972 | $-217.70 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECREATRY FOR ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.